This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Raffit Hassan, PhD
Head, Thoracic and Solid Tumor Immunotherapy Section at National Cancer Institute


Dr. Raffit Hassan is a Senior Investigator and Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute, NIH. He has played a pivotal role in validating the tumor differentiation antigen mesothelin as a target for cancer therapy and development of mesothelin targeted immunotherapy. His current research focus is on developing mesothelin directed adoptive cellular therapies including clinical trials of T cell receptor fusion constructs, gavo-cel and TC-510. Additionally, his lab has developed highly effective anti-mesothelin hYP218 CAR T cells that will soon enter the clinic.

Agenda Sessions

  • Anti-mesothelin Adoptive Cell Therapy for Solid Tumors